BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk

Dow Jones

06/22

0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. "The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships." BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

June 22, 2026 03:56 ET (07:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2645404262"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645404262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645404262?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 15:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645404262","market":"sg","top_or_hot":-1,"title":"BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 03:56 ET (07:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-22 15:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 03:56 ET (07:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRCTF","symbol_name":"BIOARCTIC AB","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645404262","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645404262","pubTimestamp":1782114960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRCTF":"BIOARCTIC AB","BK4139":"生物科技"},"translate_title":"BioArctic的第四笔BrainTransporter交易标志着平台价值不断增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRCTF":1.91},"content_text":"0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 03:56 ET (07:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}